In focus · trending topic

TULiP trial with palbociclib

1 stories · following the connections

Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer

By Nasdaq OMXDec 7, 2017, 9:05 PM UTC